AUG 30, 2016 08:00 AM PDT

Delivery solutions for robust CRISPR-based genomic editing in stem cells for disease model generation

Speakers
  • Staff Scientist, Cell Biology, Thermo Fisher Scientific
    Biography
      Nektaria Andronikou joined the research and development team at Thermo Fisher Scientific in 2010 working within the R&D transfection delivery team. She is currently involved in the development of delivery technologies targeting relevant cellular models and in vivo systems that will enable the use of exciting new technologies, such as CRISPR, messengerRNA and cell therapy. Nektaria began her professional career at ISIS Pharmaceuticals, as a research associate for the Cardiovascular Drug Discovery program, screening numerous pre-clinical targets that led to the discovery of the now FDA approved antisense drug, Kynamro. She received a Bachelor of Science in Biochemistry with a minor in Cellular and Molecular Biology from UCSD.

    Abstract:
    Stem cells, specifically induced pluripotent stem cells (iPSCs), offer exciting potential for the future of cell therapy and regenerative medicine. More recently, genetic engineering of stem cells and progenitor lines is enabling in vitro disease modeling for drug development with cell populations that would otherwise be unavailable from live donors.  With the use of TALENs and CRISPRs, this true power is fast approaching.  Having the ability to develop two cell models with isogenic background, except for the site specific edit, gives researchers the potential to study the true effects of a single mutation in a pathway or syndrome.  However, the lack of advanced technologies has been hindering the current pace of research and discovery.  Improved delivery can help accelerate research for emerging new therapies and help the understanding of disease pathways and mechanisms.  We will review multiple delivery solutions for CRISPR based technologies and also highlight protocol details and data outcomes for an iPSC specific CRISPR experiment.

    Show Resources
    You May Also Like
    MAY 22, 2018 08:00 AM PDT
    C.E. CREDITS
    MAY 22, 2018 08:00 AM PDT
    DATE: May 22, 2018TIME: 08:00AM PDT The nuclear receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are closely related transcription factors that...
    MAY 24, 2018 09:30 AM PDT
    C.E. CREDITS
    MAY 24, 2018 09:30 AM PDT
    DATE: May 24, 2018 TIME: 9:30PM PDT The current gold standard in in vitro pre-clinical cancer treatment screening remain cell lines,...
    MAY 03, 2018 11:00 AM PDT
    MAY 03, 2018 11:00 AM PDT
    DATE: May 3, 2018TIME: 11:00AM PDT, 2:00PM EDTWhile stress is one of the leading causes of neuropsychiatric disorders, the molecular underpinnings of how stress induces alterations in b...
    APR 27, 2018 10:00 AM PDT
    C.E. CREDITS
    APR 27, 2018 10:00 AM PDT
    DATE: April 27, 2018TIME: 10:00am PST, 1:00pm ESTGlioblastoma (GBM) and Medulloblastoma (MB) are the most common adult and paediatric brain tumours, both of which can have devastating c...
    AUG 15, 2018 08:00 AM PDT
    C.E. CREDITS
    AUG 15, 2018 08:00 AM PDT
    DATE: August 15, 2018TIME: 08:00AM PDT, 11:00AM EDTThe failure of current chemotherapeutic strategies in the fight against cancer can be largely attributed to the occurrence of drug res...
    OCT 19, 2017 08:00 AM PDT
    C.E. CREDITS
    OCT 19, 2017 08:00 AM PDT
    DATE: October 19, 2017TIME: 08:00am PDT, 11:00am EDT Recent FDA approval of the first Chimeric Antigen Receptor T cell (CAR-T) therapy offers cancer patients more promise than...
    Loading Comments...